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Summary
Despite recent advancements in the treatment of late-stage mutant BRAF V600E/K melanomas, a
major hurdle continues to be acquired resistance to BRAF inhibitors such as Vemurafenib. The
mechanisms for resistance have proven to be heterogeneous, emphasizing the need to utilize broad
therapeutic approachs. The present study, “Stat3 targeted therapies overcome the acquired
resistance to vemurafenib in melanomas” by Liu et al., proposes that STAT3-PAX3 signaling may
be a mechanism that is utilized by melanomas to resist RAF inhibitors.
Mutations in the serine/threonine kinase BRAF are found in 45–50% of melanomas. The
development of clinical inhibitors to steps in the BRAF-MEK-ERK1/2 pathway have led to
FDA-approval of the RAF inhibitor vemurafenib in late-stage mutant BRAF V600E/K
melanomas. However, the initial clinical responses to vemurafenib are heterogeneous, with
median progression-free survival of only 6–7 months. Almost all patients who experience an
initial response ultimately acquire resistance that allows disease progression, emphasizing
the need to identify and target mechanisms of resistance both to vemurafenib and to other
RAF inhibitors. Several mechanisms employed by mutant BRAF melanoma cells to
overcome RAF inhibition have been described previously (Aplin et al., 2011). Most of these
mechanisms, such as expression of BRAF splice variants, COT1 expression, and activating
MEK1 or NRAS mutations, funnel through the ERK1/2 pathway and lead to its re-
activation. In this paper, Liu et al. implicate an alternative signaling pathway, signal
transducer and activator of transcription 3 (STAT3)–paired box 3 (PAX3), in RAF inhibitor-
resistance in melanoma.
STAT3 is a cytokine-regulated transcription factor activated by Janus kinases (JAKs), a
family of non-receptor tyrosine kinases. JAKs phosphorylate STAT3 directly, inducing their
dimerization and subsequent nuclear translocation. Recent work from the Cui laboratory has
demonstrated STAT3 as a direct transactivator of the PAX3 promoter (Dong et al., 2012).
PAX3, a transcription factor belonging to the paired class homeodomain family, has been
implicated in activating expression of the receptor tyrosine kinase MET in melanoma
(Mascarenhas et al., 2010). In the current study, Liu and colleagues show that mutant V600E
BRAF enhances STAT3 phosphorylation and increases PAX3 expression in melanocytes.
Targeting mutant BRAF signaling with vemurafenib inhibits STAT3 phosphorylation and
expression of PAX3; this effect is attenuated but not eliminated completely in vemurafenib-
resistant melanoma cells. These data seemingly oppose previous findings that inhibition of
MEK, the downstream target of BRAF, leads to increased STAT3 phosphorylation
(Krasilnikov et al., 2003).
Nevertheless, a striking observation is that over-expression of a constitutively active form of
STAT3 or wild-type PAX3 renders mutant BRAF melanoma cells more resistant to
vemurafenib in vitro. An interesting future avenue would be to address mechanistically how
PAX3 contributes to the resistant phenotype. Additionally, these results await support from
vemurafenib-treated patient samples to determine whether PAX3 expression correlates with
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responses. Another aspect of the work is the extrapolation from previous studies
demonstrating that secreted basic fibroblast growth factor 2 (bFGF2) derived from
keratinocytes activates STAT3 in melanocytic cells (Dong et al., 2012). The authors
hypothesize that bFGF2 secreted by melanoma cells as well as keratinocytes and fibroblasts
in the tumor microenvironment ultimately lead to PAX3 expression. In the present study,
Liu and colleagues were able to detect elevated levels of secreted bFGF2 in media of
vemurafenib resistant cells when compared to their sensitive parental counterpart.
Additionally, the authors demonstrate that bFGF2 secretion in human primary fibroblasts
and human primary keratinocytes is enhanced in a dose dependent manner when exposed to
vemurafenib. These data suggest that bFGF2 secretion is elicited via an unknown
mechanism as a “protective” measure against vemurafenib treatment. Future studies may be
able to link this vemurafenib induced bFGF2 secretion observed from cells present in the
tumor micro-environment to STAT3 signaling and BRAF inhibitor resistance. Indeed, there
is increasing evidence that stromal-derived factors modulate responses to RAF inhibitors
(Straussman et al., 2012).
Liu et al. highlight the importance of the STAT3-PAX3 signaling axis using knockdown
experiments and WP1066, a STAT3 inhibitor. Knockdown of either STAT3 or PAX3 in
vemurafenib resistant cells reduced growth significantly. Furthermore, STAT3 knockdown
enhanced cell’s susceptibility to vemurafenib substantially, yielding proof of principal for
pre-clinical examination of WP1066, a small molecule STAT3 inhibitor. Earlier work with
WP1066 has demonstrated its ability to block phosphorylation of JAK2 and STAT3, reduce
melanoma proliferation, and diminish tumor growth in vivo (Kong et al., 2008). In the
present study, WP1066 inhibited phosphorylation of STAT3 and reduced downstream levels
of PAX3, irrespective of vemurafenib sensitivity status. In addition, combined treatment
with vemurafenib and WP1066 decreased the number of vemurafenib-resistant cells more
effectively than either drug alone. While the current work has yet to determine whether there
is mechanistic cooperation between V600E BRAF inhibition though vemurafenib and
WP1066 elicited reduction in activated STAT3, it suggests that STAT3 targeting in
melanoma may be effective. Dosing curves of these drugs in conjunction with either
knockdown or overexpression studies may provide better insight into potential synergies.
Because STAT3 signaling seems to be a necessary pathway for melanoma cell viability,
these findings have translational implications as they may provide a broad therapeutic
strategy for targeting the heterogeneity of vemurafenib-resistance mechanisms, akin to the
notion recently proposed for HSP90 inhibitors (Paraiso et al., 2012). Although STAT3
inhibitors such as WP1066 have yet to be evaluated fully in the clinic, JAK2/STAT3
inhibitors are currently in Phase I/II clinical trials for head and neck tumors and lymphomas.
The present study lays a foundation for additional preclinical studies on the use of WP1066
and other STAT3 inhibitors in patients with vemurafenib-resistant melanomas.
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Clinical implications
1. STAT3 activity and PAX3 levels may modulate responses to RAF inhibitors in
mutant BRAF melanomas.
2. STAT3 inhibitors are currently being tested in clinical trials.
3. Both autocrine and paracrine mechanisms may regulate STAT3-PAX3 signaling
in response to RAF inhibitors.
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